138 related articles for article (PubMed ID: 36729766)
21. Genetic Pathways in Peritoneal Mesothelioma Tumorigenesis.
Panagopoulos I; Andersen K; Brunetti M; Gorunova L; Davidson B; Lund-Iversen M; Micci F; Heim S
Cancer Genomics Proteomics; 2023; 20(4):363-374. PubMed ID: 37400148
[TBL] [Abstract][Full Text] [Related]
22. The Significance of Short Latency in Mesothelioma for Attribution of Causation: Report of a Case with Predisposing Germline Mutations and Review of the Literature.
Klebe S; Hocking AJ; Soeberg M; Leigh J
Int J Environ Res Public Health; 2021 Dec; 18(24):. PubMed ID: 34948918
[TBL] [Abstract][Full Text] [Related]
23. Malignant Mesothelioma With
Ren H; Rassekh SR; Lacson A; Lee CH; Dickson BC; Chung CT; Lee AF
Pediatr Dev Pathol; 2021; 24(6):570-574. PubMed ID: 34121509
[TBL] [Abstract][Full Text] [Related]
24. First case report of malignant peritoneal mesothelioma and oral verrucous carcinoma in a patient with a germline PTEN mutation: a combination of extremely rare diseases with probable further implications.
Löffler MW; Steinhilber J; Hilke FJ; Haen SP; Bösmüller H; Montes-Mojarro IA; Bonzheim I; Stäbler A; Faust U; Grasshoff U; Königsrainer I; Rammensee HG; Kanz L; Königsrainer A; Beckert S; Riess O; Schroeder C
BMC Med Genet; 2018 Aug; 19(1):144. PubMed ID: 30111295
[TBL] [Abstract][Full Text] [Related]
25. Progression of Peritoneal Mesothelioma In Situ to Invasive Mesothelioma Arising in the Setting of Endometriosis With Germline BAP1 Mutation: A Case Report.
Fels Elliott DR; Travieso JL; As-Sanie S; Hrycaj SM; Lieberman RW; Myers JL; Huang T
Int J Gynecol Pathol; 2022 Sep; 41(5):535-540. PubMed ID: 34723845
[TBL] [Abstract][Full Text] [Related]
26. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
[TBL] [Abstract][Full Text] [Related]
27. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
[TBL] [Abstract][Full Text] [Related]
29. Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X.
Joseph NM; Chen YY; Nasr A; Yeh I; Talevich E; Onodera C; Bastian BC; Rabban JT; Garg K; Zaloudek C; Solomon DA
Mod Pathol; 2017 Feb; 30(2):246-254. PubMed ID: 27813512
[TBL] [Abstract][Full Text] [Related]
30. Well-differentiated papillary mesothelioma of the female peritoneum: a clinicopathologic study of 26 cases.
Malpica A; Sant'Ambrogio S; Deavers MT; Silva EG
Am J Surg Pathol; 2012 Jan; 36(1):117-27. PubMed ID: 22024662
[TBL] [Abstract][Full Text] [Related]
31. Desmoid-type fibromatosis in the setting of malignant peritoneal mesothelioma: a case report of two rare diseases.
Gregory SN; Satterwhite AA; Alexander HR; Blakely AM
World J Surg Oncol; 2022 Sep; 20(1):317. PubMed ID: 36171577
[TBL] [Abstract][Full Text] [Related]
32. p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
Ito T; Hamasaki M; Matsumoto S; Hiroshima K; Tsujimura T; Kawai T; Shimao Y; Marutsuka K; Moriguchi S; Maruyama R; Miyamoto S; Nabeshima K
Am J Clin Pathol; 2015 Jun; 143(6):830-8. PubMed ID: 25972325
[TBL] [Abstract][Full Text] [Related]
33. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
[TBL] [Abstract][Full Text] [Related]
34. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma.
Tan GH; Cheung M; Chanyaputhipong J; Soo KC; Teo MC
Ann Acad Med Singap; 2013 Jun; 42(6):291-6. PubMed ID: 23842770
[TBL] [Abstract][Full Text] [Related]
35. Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.
Ribeiro C; Campelos S; Moura CS; Machado JC; Justino A; Parente B
Ann Oncol; 2013 Aug; 24(8):2147-50. PubMed ID: 23585512
[TBL] [Abstract][Full Text] [Related]
36. A diagnostic approach to paratesticular lesions with tubulopapillary architecture: a series of 16 serous borderline tumors/low-grade serous carcinoma and 14 well-differentiated papillary mesothelial tumors and mesothelioma.
Zafar R; Schrader LJ; Cheville JC; Schoolmeester JK; Roden AC; Aubry MC; Yi ES; Raghunathan A; Herrera-Hernandez L; Thompson RH; Boorjian SA; Leibovich BC; Keeney GL; Jimenez RE; Gupta S
Hum Pathol; 2022 Oct; 128():31-47. PubMed ID: 35809685
[TBL] [Abstract][Full Text] [Related]
37. Peritoneal mesothelioma in Sweden: A population-based study.
Cashin PH; Jansson Palmer G; Asplund D; Graf W; Syk I
Cancer Med; 2019 Oct; 8(14):6468-6475. PubMed ID: 31483564
[TBL] [Abstract][Full Text] [Related]
38. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
Dagogo-Jack I; Madison RW; Lennerz JK; Chen KT; Hopkins JF; Schrock AB; Ritterhouse LL; Lester A; Wharton KA; Mino-Kenudson M; Danziger N; Hung YP; Mata DA; Ross JS
JCO Precis Oncol; 2022 Jun; 6():e2100422. PubMed ID: 35704798
[TBL] [Abstract][Full Text] [Related]
39. Malignant peritoneal mesothelioma.
Loggie BW
Curr Treat Options Oncol; 2001 Oct; 2(5):395-9. PubMed ID: 12057102
[TBL] [Abstract][Full Text] [Related]
40. ['Malignant peritoneal mesothelioma': a condition difficult to diagnose].
van der Valk FM; van Leeuwen J
Ned Tijdschr Geneeskd; 2012; 156(15):A4269. PubMed ID: 22495008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]